About SCOPESCREEN
SCOPESCREEN is a Healthcare company based in Brighton (United States) founded in 1991, and was acquired by Calibre Scientific in January 2024. Specialized medical products for male fertility evaluation are manufactured. SCOPESCREEN offers products and services including QC-Beads®, CitricScreen, FructoScreen, LeucoScreen, and ImmunoSpheres® Anti-IgA. Its focus areas include Life Sciences, Genitourinary Disorders, In Vitro Diagnostic Tests and Male Fertility. Its competitors include Sandstone Diagnostics and Androvia LifeSciences; 1 of its 2 listed competitors has raised funding.
Company details
SCOPESCREEN was founded in 1991 and is based in Brighton, United States. Operations center on the medical sector, with products developed for assessing male fertility. Key offerings include AcroScreen, used to detect acrosin activity in spermatozoa; CitricScreen, for measuring citric acid in seminal plasma; and additional tests for identifying anti-sperm antibodies and granulocytes in semen samples.
- Headquarters Brighton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website scopescreen.com
- Social LinkedIn YouTube
- Acquired by Calibre Scientific (Jan 2024)
- Investors
- Acquired byCalibre Scientific
(Jan 2024)
Products & Services of SCOPESCREEN
SCOPESCREEN offers a comprehensive portfolio of products and services, including QC-Beads®, CitricScreen, FructoScreen, LeucoScreen, and ImmunoSpheres® Anti-IgA.
Quality control beads for diagnostic accuracy in testing.
Screen for citric acid in fertility assessments.
Kit for fructose detection in reproductive health evaluations.
Tool for leukocyte analysis in diagnostic procedures.
Beads for detecting IgA antibodies in immune evaluations.
Apps and channels of SCOPESCREEN
its YouTube channel Alpha-Tec Systems has 494 subscribers and 13 videos.
Videos from SCOPESCREEN
The most watched videos on SCOPESCREEN's YouTube channel, Alpha-Tec Systems (494 subscribers). Click a video to play it here.
More on Alpha-Tec Systems.
Investors in SCOPESCREEN
SCOPESCREEN has secured backing from 1 investor. Prominent investors backing the company include Calibre Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of contract based research, manufacturing, distribution and other services for biopharma sector | 2016 | calibrescientific.com | Los Angeles, United States |
Investor details for SCOPESCREEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SCOPESCREEN
2 dated milestones of SCOPESCREEN across 33 years, from founding to its latest funding, stage changes and deals.
- Founded SCOPESCREEN is founded.
- Exit Acquired by Calibre Scientific.
Competitors of SCOPESCREEN
SCOPESCREEN has 2 listed competitors in our database, 1 of them funded. They include Sandstone Diagnostics and Androvia LifeSciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sandstonedx.com | 2012 | Pleasanton, United States | $11.97M | Provides rapid tests for accurate sperm count diagnostics. | ||
| androvialifesciences.com | 2015 | New York, United States | Develops innovative biomarker-based assays for male fertility testing. |
Detailed competitors of SCOPESCREEN
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
3 companies that operate in the same segment as SCOPESCREEN (Genitourinary Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scopescreen
Complete news archive for SCOPESCREEN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SCOPESCREEN
SCOPESCREEN was founded in 1991.
SCOPESCREEN is headquartered in Brighton, United States. It is registered at Brighton, Colorado, United States.
SCOPESCREEN was founded in 1991 and is based in Brighton, United States. Operations center on the medical sector, with products developed for assessing male fertility. Key offerings include AcroScreen, used to detect acrosin activity in spermatozoa; CitricScreen, for measuring citric acid in seminal plasma; and additional tests for identifying anti-sperm antibodies and granulocytes in semen samples.
SCOPESCREEN's top competitors include Sandstone Diagnostics and Androvia LifeSciences.
SCOPESCREEN offers QC-Beads®, CitricScreen, FructoScreen, LeucoScreen, and ImmunoSpheres® Anti-IgA.
SCOPESCREEN has 1 investor. Key investors include Calibre Scientific.
Yes. SCOPESCREEN was acquired by Calibre Scientific in January 2024.